Innate Pharma Files 6-K Report
Ticker: IPHA · Form: 6-K · Filed: 2026-04-08T06:16:26-04:00
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer
TL;DR
Innate Pharma filed a 6-K on 4/8/26. Standard foreign issuer report.
AI Summary
Innate Pharma SA filed a Form 6-K on April 8, 2026. This report is for a foreign issuer and includes documents such as the 6-K itself and Exhibit 99.1. The filing details Innate Pharma's mailing and business addresses in Marseille, France.
Why It Matters
This filing indicates ongoing reporting activity for Innate Pharma SA, a foreign issuer, which is important for investors tracking the company's regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine foreign issuer filing (6-K) and does not appear to contain material new information or significant financial events.
Key Players & Entities
- Innate Pharma SA (company) — Filer of the 6-K report
- 0001598599 (company) — CIK number for Innate Pharma SA
- 2026-04-08 (date) — Filing date and period of report
FAQ
What type of filing is this 6-K for Innate Pharma SA?
This is a Form 6-K, which is a report of a foreign issuer.
When was this 6-K filing accepted by the SEC?
The filing was accepted on April 8, 2026.
What are the business and mailing addresses provided for Innate Pharma SA?
Both the business and mailing addresses are listed as 117 AVENUE DE LUMINY BP 30191 MARSEILLE FRANCE.
What is the CIK number associated with Innate Pharma SA?
The CIK number for Innate Pharma SA is 0001598599.
What SIC code is listed for Innate Pharma SA?
The SIC code listed is 2836 for Biological Products, (No Diagnostic Substances).
From the Filing
EDGAR Filing Documents for 0001628280-26-024144 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: SEC Accession No. 0001628280-26-024144 Filing Date 2026-04-08 Accepted 2026-04-08 06:16:26 Documents 2 Period of Report 2026-04-08 Document Format Files Seq Description Document Type Size 1 6-K a260408_6k-iph.htm 6-K 8509 2 EX-99.1 a260408_exhibit991.htm EX-99.1 16755 Complete submission text file 0001628280-26-024144.txt 26649 Mailing Address 117 AVENUE DE LUMINY BP 30191 MARSEILLE FRANCE France 13009 Business Address 117 AVENUE DE LUMINY BP 30191 MARSEILLE FRANCE France 13009 33430303030 Innate Pharma SA (Filer) CIK : 0001598599 (see all company filings) EIN. : 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231 LEI: 9695002Y8420ZB8HJE29 Type: 6-K | Act: 34 | File No.: 001-39084 | Film No.: 26846441 SIC : 2836 Biological Products, (No Diagnostic Substances) (CF Office: 03 Life Sciences)